Harbor Capital Advisors Inc. Decreases Stake in Option Care Health, Inc. $OPCH

Key Points

• Harbor Capital Advisors Inc. has reduced its stake in Option Care Health, Inc. by 34.7%, holding approximately 0.06% of the company valued at $3.01 million after selling nearly 50,000 shares.
• Several institutional investors have increased their stakes in Option Care Health, with notable increases from Northwestern Mutual Wealth Management Co. by 1,492.9% and Brooklyn Investment Group by 186.6% during the first quarter.
• Option Care Health reported a quarterly earnings per share of $0.41, exceeding analyst expectations, and set a guidance of $1.650 to $1.720 EPS for FY 2025, with positive analyst sentiment reflected in an average price target of $35.75 for the stock.

Harbor Capital Advisors Inc. trimmed its position in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 34.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 92,692 shares of the company's stock after selling 49,364 shares during the period. Harbor Capital Advisors Inc. owned about 0.06% of Option Care Health worth $3,011,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in OPCH. Durable Capital Partners LP bought a new position in Option Care Health in the 1st quarter worth about $122,905,000. Nuveen LLC purchased a new stake in Option Care Health during the first quarter valued at approximately $70,965,000. Allspring Global Investments Holdings LLC lifted its position in Option Care Health by 6,525,926.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,500,986 shares of the company's stock valued at $52,459,000 after acquiring an additional 1,500,963 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in Option Care Health during the fourth quarter valued at approximately $27,428,000. Finally, Fuller & Thaler Asset Management Inc. raised its holdings in shares of Option Care Health by 30.8% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 4,204,481 shares of the company's stock worth $146,947,000 after buying an additional 989,048 shares during the last quarter. 98.05% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Harry M. Jansen Kraemer, Jr. bought 36,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were acquired at an average price of $27.15 per share, for a total transaction of $977,400.00. Following the completion of the transaction, the director directly owned 375,390 shares in the company, valued at $10,191,838.50. This trade represents a 10.61% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Norman L. Wright bought 3,411 shares of the company's stock in a transaction dated Tuesday, September 9th. The stock was bought at an average price of $29.31 per share, for a total transaction of $99,976.41. Following the transaction, the director owned 15,501 shares of the company's stock, valued at approximately $454,334.31. This trade represents a 28.21% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 59,411 shares of company stock worth $1,627,576 over the last 90 days. 0.64% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on OPCH shares. Barrington Research reaffirmed an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a report on Thursday, July 10th. JMP Securities increased their price objective on shares of Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a research note on Thursday, July 31st. Finally, Citigroup reiterated an "outperform" rating on shares of Option Care Health in a research note on Thursday, July 31st. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $35.75.

Option Care Health Stock Performance

OPCH stock traded down $0.10 during midday trading on Friday, hitting $28.31. 3,364,853 shares of the stock traded hands, compared to its average volume of 1,856,958. The firm has a market cap of $4.59 billion, a P/E ratio of 22.65, a PEG ratio of 1.71 and a beta of 0.82. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.52 and a quick ratio of 1.00. The stock's fifty day simple moving average is $28.87 and its 200-day simple moving average is $31.29. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.40 by $0.01. The company had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.35 billion. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The firm's revenue was up 15.4% on a year-over-year basis. During the same quarter last year, the business earned $0.30 earnings per share. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, analysts expect that Option Care Health, Inc. will post 1.22 earnings per share for the current year.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.